At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Margetuximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients With Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH
In Brief
A Phase 2 clinical trial evaluating Margetuximab for Breast Cancer. Completed, enrolled 25 participants across 6 sites.
Detailed Summary
The purpose of this study is to determine if margetuximab is effective in the treatment of certain patients with relapsed or refractory advanced breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedApr 2013
Primary CompletionDec 2016
Study CompletionApr 2017
TodayJul 2026
First PostedApr 10, 2013
Enrollment StartMar 1, 2013
Primary CompletionDec 7, 2016
Study CompletionApr 14, 2017
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.2 years ago
Interventions
Margetuximabbiological
Anti-HER2 monoclonal antibody